Introducing PharmAlliance International Labs’ Rosuvastatin Tablets

Company Introduction:

Welcome to PharmAlliance International Labs Private Limited, where we prioritize health and wellness through our innovative pharmaceutical solutions. We are proud to introduce our flagship product, Rosuvastatin Tablets, a trusted medication for managing lipid disorders and reducing the risk of cardiovascular events.

Drug Classification:

Rosuvastatin belongs to the class of medications known as statins, or HMG-CoA reductase inhibitors. This class of drugs effectively lowers cholesterol levels in the blood by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver.

Formulations:

PharmAlliance International Labs offers Rosuvastatin Tablets in various strengths, including 5mg, 10mg, and 20mg formulations. These oral tablets are packaged in blister packs containing 10 tablets each, ensuring easy and convenient administration.

Indications:

Rosuvastatin Tablets are indicated for:

Lowering elevated levels of total cholesterol, LDL cholesterol, apolipoprotein B, and triglycerides in the blood.

Increasing levels of HDL cholesterol in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia.

Reducing the risk of cardiovascular events such as myocardial infarction, stroke, revascularization procedures, and cardiovascular mortality in patients with established cardiovascular disease or at high risk for cardiovascular events.

Usage:

Rosuvastatin Tablets should be taken orally once daily, with or without food. It is essential to follow the prescribed dosage and administration instructions provided by a healthcare professional. Regular monitoring of lipid levels and liver function tests is recommended during treatment with rosuvastatin to assess treatment response and detect any potential adverse effects.

Dosage:

The recommended starting dose of Rosuvastatin is typically 5-10 mg once daily. Dosage adjustments may be made based on the patient’s lipid profile, cardiovascular risk factors, and response to treatment. The maximum recommended dose of Rosuvastatin is 20 mg once daily for most patients.

Pharmacokinetics:

Rosuvastatin is well absorbed from the gastrointestinal tract and undergoes extensive hepatic metabolism. The primary route of elimination is via the bile, with minimal renal excretion. Rosuvastatin’s long half-life allows for once-daily dosing and sustained lipid-lowering effects.

Pharmacodynamics:

By inhibiting HMG-CoA reductase, rosuvastatin effectively lowers LDL cholesterol levels, the primary target for cardiovascular risk reduction. Rosuvastatin also modestly increases HDL cholesterol levels and reduces triglyceride levels, further contributing to its cardiovascular protective effects.

Side Effects:

Common side effects associated with rosuvastatin therapy may include headache, myalgia (muscle pain), abdominal pain, constipation, and nausea. Rare but serious adverse effects such as myopathy (muscle damage), rhabdomyolysis (severe muscle breakdown), and hepatotoxicity (liver damage) may occur and require medical attention.

Experience the superior efficacy and cardiovascular benefits of PharmAlliance International Labs’ Rosuvastatin Tablets. For more information, please contact us. We are committed to promoting heart health and enhancing patient well-being through our pharmaceutical products.